Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Bing-Xiang Wu"'
Autor:
Dan Lu, Yin-Jian Yang, Chunyan Cheng, Xi-Jie Zhu, Xin-Xin Yan, Yong-Jian Zhu, Xuan Gao, Yu-Ping Zhou, Fan Guo, Jing-Yi Li, Ke-Yi Mei, Xian-Mei Li, Tian-Yu Lian, Bing-Xiang Wu, Kai Sun, Xi-Qi Xu, Xiang Zhou, Yi-Min Mao, Zhi-Cheng Jing
Publikováno v:
SSRN Electronic Journal.
Autor:
Pingping Wang, Mengtao Li, Qiu-Shang Ji, Yang Li, Wenjing Zhu, Gang-Cheng Zhang, Jin-Ming Liu, Jinhua Zhong, Ping Zhu, Zai-Xin Yu, Bing-Xiang Wu, Zhi-Cheng Jing, Yong Huo, Xiaofeng Zeng
Publikováno v:
BMC Cardiovascular Disorders, Vol 20, Iss 1, Pp 1-8 (2020)
BMC Cardiovascular Disorders
BMC Cardiovascular Disorders
Background The efficacy and safety of ambrisentan has been previously evaluated in Chinese patients with pulmonary arterial hypertension (PAH). This post-hoc analysis assessed the efficacy and safety of ambrisentan in a subgroup of connective tissue
Autor:
Yu-Ping Zhou, Zhi-Cheng Jing, Bing-Xiang Wu, Mengtao Li, Yining Wang, Wei Ma, Cheng Hong, Wei Huang, Lan Wang, Fen-Ling Fan, Yong-Jian Zhu, Duolao Wang, Shuyang Zhang, Xin Jiang, Fu-Hua Peng, Gang-Cheng Zhang, Yunshan Cao, Zhen-Wen Yang, Feng Zhang, Xin Pan, Xi-Qi Xu
Publikováno v:
European heart journal. 42(42)
AimsThis study aimed to assess the clinical characteristics and long-term survival outcome in patients with Takayasu’s arteritis-associated pulmonary hypertension (TA-PH).Methods and resultsWe conducted a nationally representative cohort study of T
Publikováno v:
Chest. 150:367-373
This study aimed to show whether circulating bone morphogenetic proteins (BMPs) levels are associated with increased risk of mortality in patients with pulmonary arterial hypertension (PAH).A total of 156 patients with PAH including 43 with heritable
Autor:
Shuiping Zhao, Jue Li, Valentina Carubelli, Lei Pan, Benjamin Xiaoyi Li, Jianqiang Peng, Su Jiang, Chaofan Liang, Guo-Tai Sheng, Zhi-Cheng Jing, Bing-Xiang Wu, Zai-Xin Yu, Erika Salvi, Jian-Bin Gong, Xin-Li Li, Qing-Yan Zhao, Jia-Ning Cao, Dong-Ye Li
Publikováno v:
European Heart Journal Supplements. 18:A27-A36
Chronic heart failure (CHF) may be associated with an energy deficit in cardiac muscle. As levo-carnitine (LC) is involved in the production of myocardial energy, it is hypothesized that LC supplementation may ameliorate CHF symptoms. This multicentr
Autor:
Bing-Xiang Wu, Mardi Gomberg-Maitland, Lei Pan, Xin-Li Li, Yong Wang, Li-Zhi Dai, Rui Zhang, Qin-Hua Zhao, Zhen-Ning Zhang, Zhi-Cheng Jing, Xin Jiang
Publikováno v:
Heart. 97:1876-1881
Although sildenafil has been shown to be safe and effective in idiopathic pulmonary arterial hypertension (PAH) and PAH related to connective tissue disease, its effects in Eisenmenger syndrome are less clear.To investigate whether long-term treatmen
Autor:
Jing He, Weiping Xie, Rui Zhang, Zai-Xin Yu, Li-Zhi Dai, Ping Yuan, Lei Pan, Xin Jiang, Zhi-Cheng Jing, Marc Humbert, Bing-Xiang Wu
Publikováno v:
Chest. 140:301-309
In a previous study of Chinese patients with idiopathic pulmonary arterial hypertension (IPAH) in the nontargeted therapy era (defined as the time before 2006 when new pulmonary arterial hypertension-specific drugs were not available in China), we re
Autor:
Wei-Feng Wu, Xian-Sheng Cheng, Duan-Zhen Zhang, Shi-An Huang, Hong Gu, Chang-Ming Xiong, Jian-Jun Li, Guang-Liang Shan, Zhi-Hu Zhao, Xian-Yang Zhu, Wei-Jun Zhang, Tao Guo, Jian-Ying Chen, Wei-Min Li, Cheng Zhang, Zhihong Liu, Bing-Xiang Wu, Kai Huang, Ya-Juan Guo, Guang-Hua Wu, Jian-Guo He, Xian-Ling Lu, Qing Gu, Hong-Yan Tian, Hong-Min Liu, Xin-Hai Ni
Publikováno v:
Cardiovascular Therapeutics. 28:350-355
SUMMARY Background: It has been demonstrated that sildenafil is effective in patients with pulmonary arterial hypertension (PAH). However, the impact of sildenafil on PAH in adults with congenital heart disease (CHD) has been less investigated. Objec
Autor:
Yan Wu, Jielin Pu, Xin Jiang, Xi-Qi Xu, Wen Gao, Chuan-Rong Ma, Zhi-Cheng Jing, Yuejin Yang, Yong Wang, Bing-Xiang Wu
Publikováno v:
Heart. 95:1531-1536
Vardenafil is a new phosphodiesterase-5 inhibitor that has shown some efficacy in the treatment of pulmonary arterial hypertension (PAH).To examine the long-term effects of vardenafil in patients with PAH.A multicentre, open-label study of 1-year's d
Autor:
Ya-ming, Geng, Bing-xiang, Wu
Publikováno v:
Zhonghua xin xue guan bing za zhi. 40(12)